Post by PARI

How can development teams avoid Human Factors (HF) redundancy while ensuring that a platform device truly fits the needs of diverse respiratory patients? In their poster “A Novel HF User Characteristics Assessment Approach for a New Platform-Based, Breath-Triggered Nebulizer in Inhalation Therapy,” Simon Buchner, Amy MacDonald, and John DeFoggi highlight a challenge that pharma and biotech teams developing inhaled therapies know well: the need for extensive human factors testing on a combination product, even when the nebulizer component has already been thoroughly evaluated by the device manufacturer. The result is often redundant data, repeated regulatory reviews, and avoidable delays. 💡For PARI’s new platform-based, breath-triggered eFlow® Integrated nebulizer a user‑characteristics‑driven assessment offers a powerful solution. By focusing on actual user capabilities instead of disease labels and by integrating literature insights, pulmonologist input, and validated assessment tools this approach strengthens root‑cause analysis and supports earlier, more effective study design improvements. ✅ The outcome: a more robust platform nebulizer that allows pharma partners to build on existing usability evidence, minimize HF redundancy, focus on combination product–specific risks, and move faster toward regulatory success. 🔗 Find more information on this topic here: https://lnkd.in/dpBdUjDd 👉 Let’s talk about your development project. Email our BD team on [email protected] #inhalation #respiratory #drugdelivery #pharmapartnering #PharmaInnovation #Biotech #HumanFactorsEngineering #HumanFactors #Usability #PatientSafety